In-Licensing in Specialty Pharma

The emerging sector of specialty pharma-companies building a business around in-licensing poorly penetrated drugs and growing their share through targeted sales efforts-represents an increasing percentage of total dealmaking volume. But could its strategy already be suffering from diminishing returns?